A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

The purpose of this study is to determine if CP-945,598 is effective in the prevention of weight regain in obese subjects.

Key facts

Study ID

NCT00483171

Run by

Pfizer

People needed

699

Starts

2008-01-01

Expected to finish

2009-01-01

Last updated by the study team

2012-11-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be overweight (BMI) >/=30 kg/m2, for subjects without co morbidities; >/=27 kg/m2 for subjects with co morbidities
• Subjects who are willing and able to comply with 8 week Low Calorie Diet, scheduled visits, treatment plan, laboratory tests, and other trial procedures.

You may not qualify if…

• Participation in a formal weight loss program or significant weight loss (fluctuation >5% of total body weight) in the past 3 months.
• Subjects with serious medical or psychiatric conditions

Where it is running

• Pfizer Investigational Site — La Jolla, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Baton Rouge, Louisiana, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — St Louis, Missouri, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Durham, North Carolina, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Seattle, Washington, United States
• Pfizer Investigational Site — Camperdown, New South Wales, Australia
• Pfizer Investigational Site — Kippa-Ring, Queensland, Australia
• Pfizer Investigational Site — Adelaide, South Australia, Australia
• Pfizer Investigational Site — Bedford Park, South Australia, Australia
• Pfizer Investigational Site — Heidelberg, Victoria, Australia
• Pfizer Investigational Site — Aarhus, Denmark
• Pfizer Investigational Site — Frederiksberg C, Denmark
• Pfizer Investigational Site — Gentofte Municipality, Denmark
• Pfizer Investigational Site — Roskilde, Denmark
• Pfizer Investigational Site — Almere Stad, Netherlands
• Pfizer Investigational Site — Amsterdam, Netherlands
• Pfizer Investigational Site — Amsterdam, Netherlands
• Pfizer Investigational Site — Hilversum, Netherlands
• Pfizer Investigational Site — Cape Town, Gauteng, South Africa
• Pfizer Investigational Site — Johannesburg, Gauteng, South Africa
• Pfizer Investigational Site — Pretoria, Gauteng, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.